Bradley A Warady, Pablo E Pergola, Rajiv Agarwal, Sharon Andreoli, Gerald B Appel, Sripal Bangalore, Geoffrey A Block, Arlene B Chapman, Melanie P Chin, Keisha L Gibson, Angie Goldsberry, Kazumoto Iijima, Lesley A Inker, Clifford E Kashtan, Bertrand Knebelmann, Laura H Mariani, Colin J Meyer, Kandai Nozu, Megan O'Grady, Michelle N Rheault, Arnold L Silva, Peter Stenvinkel, Roser Torra, Glenn M Chertow
BACKGROUND AND OBJECTIVES: Alport syndrome is an inherited disease characterized by progressive loss of kidney function. We aimed to evaluate the safety and efficacy of bardoxolone methyl in patients with Alport syndrome. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We randomly assigned patients with Alport syndrome, ages 12-70 years and eGFR 30-90 ml/min per 1.73 m2 , to bardoxolone methyl ( n =77) or placebo ( n =80). Primary efficacy end points were change from baseline in eGFR at weeks 48 and 100...
December 2022: Clinical Journal of the American Society of Nephrology: CJASN